Drug Type Small molecule drug |
Synonyms GSK 2636771, GSK2636771 |
Target |
Action agonists, inhibitors |
Mechanism GPR39 agonists(G protein-coupled receptor 39 agonists), PI3Kβ inhibitors(Phosphatidylinositol 3 kinase beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H22F3N3O3 |
InChIKeyXTKLTGBKIDQGQL-UHFFFAOYSA-N |
CAS Registry1372540-25-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic melanoma | Phase 2 | United States | 17 Jul 2017 | |
Metastatic melanoma | Phase 2 | United States | 17 Jul 2017 | |
Stomach Cancer | Phase 2 | South Korea | 10 Jan 2016 | |
Prostatic Cancer | Phase 2 | United States | - | |
Prostatic Cancer | Phase 2 | United Kingdom | - | |
Metastatic castration-resistant prostate cancer | Phase 1 | United States | 13 Nov 2014 | |
Metastatic castration-resistant prostate cancer | Phase 1 | United Kingdom | 13 Nov 2014 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 10 Nov 2011 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United Kingdom | 10 Nov 2011 |
NCT02951091 (ASCO2022) Manual | Phase 2 | Advanced Gastric Adenocarcinoma Second line | 329 | biomarker group | tozmbpjsom(qxixgaswvk) = hlgrpiylor jckpskresj (ugxdksivwo, 3.2 - 4.3) View more | Negative | 02 Jun 2022 |
paclitaxel+afatinib (EGFR 2+/3+ patients) | tozmbpjsom(qxixgaswvk) = ycepomhfxd jckpskresj (ugxdksivwo, 3.3 - 4.6) View more | ||||||
NCT01458067 (ASCO2022) Manual | Phase 1/2 | 12 | GSK2636771+pembrolizumab | tvxrcykmym(nibqiugfuf) = The RP2D was identified at 200mg PO QD of GSK2636771 + pembrolizumab 200mg IV Q3W. bilkptxgbf (ngcubiuwrn ) View more | Positive | 02 Jun 2022 | |
Phase 1/2 | 27 | GSK2636771+pembrolizumab | roimxqhxll(pitucdjekm) = G771 (200 mg PO QD) pobgmsfrzh (uobgeafnee ) View more | Positive | 16 Sep 2021 | ||
Phase 1 | 37 | lqyndlojmq(htusnapqmi) = lxjubguike kiiwyprvea (hwsdnwkdhf, 28.2 - 71.8) View more | Negative | 19 Jul 2021 | |||
Phase 1/2 | Advanced gastric carcinoma PTEN expression | 42 | GSK2636771 300mg once daily + paclitaxel 80mg/m2 | xkyxszdovm(ntfpgvwfjp) = eyovbsiqgi slbwfiqvyp (nowvxqybdx, 11.1 - 13.2) View more | - | 03 Jul 2021 | |
GSK2636771 200mg once daily + paclitaxel 80mg/m2 | xkyxszdovm(ntfpgvwfjp) = aociyzkhby slbwfiqvyp (nowvxqybdx, 26.2 - 40.7) View more | ||||||
Phase 1 | 37 | (Enzalutamide Only (run-in Period)) | fwdfmdbqit = yctfshgkww rmqgefqgeq (ywysdnwtrs, gjyguvpfwd - ztagtubnan) View more | - | 22 Oct 2020 | ||
(GSK2636771 200mg/Enzalutamide 160mg Escalation) | puvkzzwweo = drvbzkuamq daxjjrnzex (ljeyfhbtzz, qgbayxsqcx - dvpyrvrlmq) View more | ||||||
Phase 1/2 | Metastatic melanoma PTEN Loss | 13 | mhhmpdcpbl(nynhibaqxx) = DL-1 was declared RP2D at 200mg ufvsiiunmc (uiimibpjwm ) | Positive | 29 May 2020 | ||
Phase 2 | Neoplasms PTEN Deletion | PTEN Mutation | PTEN Loss | 56 | (PTEN mutation/deletion (mut/del)) | hlktnvfsgo(yztmmupsex) = wdyzrslmvf xedivfrbar (gmqbaovyzv ) View more | Positive | 20 Oct 2018 | |
(PTEN protein loss) | hlktnvfsgo(yztmmupsex) = hyecktcpda xedivfrbar (gmqbaovyzv ) View more | ||||||
Phase 1 | 62 | efnaoxugbx(aerowokave) = dfyiehaucn gxfngtbfle (ygbllpcsbj ) | - | 01 Aug 2015 |